Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects

NCT03330197 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT03330197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03330197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects
Lead sponsor
Alaunos Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
September 26, 2017
Completion date
September 10, 2021
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, pediatric brain tumor